Medication info
Telmidipine Tablets 80/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Telmidipine Tablets 80/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets / bottle
Approval status
Active

MFDS item code 202500492 · Approved 2025.03.05 · Insurance code 657808360

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular disease risk
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take the tablet at the same time every day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination together with rosuvastatin alone, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with an individual component as described below, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In elderly patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased up to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Since systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, the Cmax of rosuvastatin increased approximately 2.4-fold and its AUC increased approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risks due to the increase in rosuvastatin Cmax and monitor the patient closely.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • cardiovascular disease risk factor
  • stroke risk
  • myocardial infarction risk
View approved original text

This medication is used for patients with essential hypertension who are not adequately controlled with the combination of Telmisartan and Amlodipine, as well as for patients with hyperlipidemia requiring Rosuvastatin Calcium. The Telmisartan/Amlodipine combination aids in effectively lowering blood pressure. Rosuvastatin is utilized as an adjunct in various lipid disorders such as primary hypercholesterolemia or mixed dyslipidemia when dietary changes and exercise are insufficient, and it also applies to heterozygous familial hypercholesterolemia and dysbetalipoproteinemia. Furthermore, it helps lower cholesterol levels in patients with hypercholesterolemia, delays the progression of atherosclerosis, and reduces the risk of stroke, myocardial infarction, and revascularization surgeries in high-risk cardiovascular disease patients with elevated high-sensitivity C-reactive protein levels. Therefore, this medication is effective for controlling blood pressure and preventing cardiovascular diseases.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take the tablet at the same time every day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination together with rosuvastatin alone, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with an individual component as described below, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In elderly patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased up to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Since systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, the Cmax of rosuvastatin increased approximately 2.4-fold and its AUC increased approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risks due to the increase in rosuvastatin Cmax and monitor the patient closely.

Precautions

This medication can cause serious harm to the fetus and newborn if administered to pregnant women, so its use must be discontinued immediately upon confirmation of pregnancy. Patients allergic to any of the active ingredients or related components, those with certain hereditary angioedema, and patients with severe liver or kidney dysfunction should not take this medication. Elderly patients, those with hypotension, compromised liver function, and patients with high serum potassium levels must use this medication cautiously and may require regular check-ups as necessary. If symptoms such as muscle pain, weakness, or cramps occur during treatment, consult a doctor immediately, and muscle enzyme tests may be necessary. This medication may affect liver function; therefore, it is important to periodically conduct liver function tests before and during treatment. Interactions may occur when taken with other medications, so inform healthcare professionals of any other medications being taken. This medication is not recommended for breastfeeding women, and if it must be taken, breastfeeding should be discontinued. In case of overdose, severe hypotension, dizziness, or arrhythmias may occur; seek medical attention immediately. It is not recommended for use in children and adolescents under 18, as safety and effectiveness have not been sufficiently confirmed. Store this medication out of reach of children and avoid transferring it to another container.

Side effects

Viral upper respiratory tract infection, dyspnea, rectal bleeding, dyspepsia, atopic dermatitis, peripheral edema, chronic gastritis, various gastrointestinal disorders, hiatal hernia, dysuria, rhinitis, pharyngeal discomfort, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasms, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory tract infection, low back pain, sinusitis, diarrhea, pharyngitis, erectile dysfunction, increased sweating, flushing, allergies, fever, leg pain, malaise, palpitations, dependent edema, angina pectoris, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, sensory abnormalities, involuntary muscle contractions, dermatitis, rash, eczema, itching, angioedema, frequent urination, cystitis, cerebrovascular disease, visual disturbances, conjunctivitis, ear pain, headache, fatigue, nausea, abdominal pain, drowsiness, arrhythmia, bradycardia, chest pain, peripheral ischemia, syncope, orthostatic hypotension, vasculitis, peripheral neuropathy, tremors, loss of appetite, constipation, dysphagia, pancreatitis, vomiting, gingival hyperplasia, allergic reaction, burning sensation, malaise, rigidity, weight gain, weight loss, arthralgia, arthritis, muscle cramps, myalgia, erectile dysfunction, insomnia, neuroasthenia, depression, abnormal dreams, anxiety, depersonalization, dyspnea, nasal bleeding, angioedema, polymorphic erythema, rash, erythematous rash, papular rash, diplopia, ocular pain, frequent urination, urinary disturbances, nocturia, dry mouth, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia with systemic symptom drug reaction syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, hypotension, tachycardia, bradycardia, acute renal failure, angioedema, thrombocytopenia, increased serum creatinine, musculoskeletal pain, neck pain, nasopharyngitis, upper abdominal discomfort, orthostatic dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container that blocks light, safely kept at a temperature between 1°C and 30°C. This storage method will maintain the medication's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets / bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.